Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis D A Spencer
Bronchodilators syndrome occurring in association with ipratropium. 13 Nebulised bronchodilators are used extensively in children with cystic fibrosis, but in many Optimal dosage regimens for agonists have not been investigated, and doses given to chilinstances this use is not yet based on objective evidence of clinical benefit. dren with cystic fibrosis are usually similar to those used in asthma. It has been suggested that these doses should be calculated according to body weight, 14 but whether this refinement    is of any practical significance in cystic fibrosis The main effect of bronchodilators is probably is unknown. to reduce smooth muscle spasm in the airways If a decision has been made to give inhaled of patients with cystic fibrosis. In addition, bronchodilators to a child with cystic fibrosis, improved mucociliary clearance has been selection of the mode of administration deshown in vivo following subcutaneous adserves careful consideration because the time ministration of terbutaline to adults with cystic and effort taken to deliver nebulised bronchofibrosis 1 and also, theoretically, agonists might dilators is of critical importance if other reduce inflammatory damage. 2 The relative nebulised treatments such as antibiotics and importance of these mechanisms and their clinrhDNase are prescribed concurrently. Mixing ical relevance are unknown.
of antibiotics and rhDNase in the same nebuThe occurrence of reversible airways obliser chamber is not recommended 15 and an struction in children with cystic fibrosis is interval of 30 minutes should be allowed belargely a reflection of the frequency of asthma tween giving these two medications. Such rein the whole paediatric population (perhaps gimens are onerous and to allow children to 15%), as well as an increase in bronchial refollow a near normal lifestyle it is imperative sponsiveness secondary to the complex chronic to avoid giving nebulised bronchodilators when inflammation present in their airways. 3 Over a administration by hand held inhalers would be third of patients with cystic fibrosis will show equally effective. evidence of reversible airways obstruction at some time, but the response in individuals is extremely variable. [4] [5] [6] The interpretation of these results is hampered by poor re-Antibiotics producibility of pulmonary function meas-The use of nebulised antibiotics is discussed in urements. 7 In view of this variability a detail in the paper by Webb and Dodd on pp therapeutic trial of regular agonists is ap-S69-71. Here the use of nebulised antibiotics is propriate in children with cystic fibrosis who considered specifically in relation to paediatric wheeze, or in cases where there is a marked practice. improvement in symptoms or pulmonary funcThe study by Valerius et al 16 demonstrated tion following a test dose. 8 The routine use of that chronic colonisation with Pseudomonas methacholine challenge is not recommended. aeruginosa in patients with cystic fibrosis could It is not known whether the responses to be delayed by the use of oral ciprofloxacin agonists or anticholinergic agents vary with age. and nebulised colistin. Longer term studies are required to determine the duration of benefit and whether repeated courses of treatment are beneficial or whether P aeruginosa is isolated  Ipratropium bromide has been shown to cause again at a later date.
Pseudomonas aeruginosa is usually first isolbronchodilatation when given to children and adults with cystic fibrosis. 9 10 In a separate study ated from patients in childhood. At this time there is often significant acute or subacute in children there was no evidence of acute bronchodilatation with either salbutamol or clinical deterioration with an increase in respiratory symptoms, weight loss or a failure to ipratropium but a reduction in bronchial re-
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activity to methacholine was demonstrated. Correspondence to:
fibrosis in the UK, probably because of There have been no published studies to long to continue nebulised colistin in patients USA 25 and the UK, 26 even though data with which to formulate them are scanty. These without new symptoms, or whether it may be advantageous to remain on this medication guidelines, however, are not intended to be proscriptive and it is emphasised that patients indefinitely in view of the poorer prognosis associated with chronic infection. 17 with a broad spectrum of pulmonary disease may benefit. The UK guidelines suggest that Similarly, it is not yet known whether initiating treatment with long term nebulised anti-patients likely to benefit would fulfil the following criteria: (1) aged over five years; (2) pseudomonal antibiotics at the time of diagnosis may delay or prevent the onset of have purulent sputum or, in young children, a productive cough; (3) have had more than one colonisation.
exacerbation of respiratory infection requiring intravenous antibiotics in the last 12 months; (4) a forced vital capacity of <80% predicted   A face mask should be used instead of a mouth-for height when in a stable state; and (5) be compliant with previous treatments. piece in infants and younger children who will not tolerate one. Nasal deposition of drugs may
It is recommended that treatment should be initiated under the direct supervision of a cystic be less important in this age group than in adults.
18 A lower flow compressor with an active fibrosis specialist. Most children with moderate suppurative disease can be managed as outVenturi system is preferred for children.
patients but those with severe or unstable disease may be better beginning treatment as an inpatient under the close supervision of a cystic rhDNase Treatment of cystic fibrosis with nebulised fibrosis physiotherapist.
The recommended starting dose is 2.5 mg rhDNase is considered in detail in the paper by Conway and Watson on pp S64-68. The once daily. Occasional patients may benefit from an increase to 2.5 mg twice daily, but following discussion concerns particular aspects relevant to children.
there is no evidence of any further benefit from a larger daily dose. Only 30% of patients treated rhDNase administered by nebuliser in a dose of 2.5 mg once daily to patients with cystic will have a statistically significant improvement in pulmonary function 27 and a therapeutic trial fibrosis with moderately severe suppurative lung disease results in a small but significant is necessary in each case. The optimal duration of such a trial is uncertain. Although most improvement in pulmonary function with a mean increase of about 6% in forced expiratory patients with moderately severe disease show a response within 14 days, children with more volume in one second.
19-21 The onset of benefit is rapid and appears to be maintained for the severe disease may require a trial of up to, perhaps, three months. duration of treatment, at least up to 24 weeks. 22 Pulmonary function returns to the previous The current guidelines 25 26 assess outcome mainly in terms of improvement in pulmonary baseline within 48 hours of discontinuance. Treatment appears to be safe, with the only function. They take no account of subjective benefits and improved well being resulting from consistent adverse effect being mild pharyngitis. Longer term treatment is associated with easier expectoration of sputum and there is, as yet, no published information on quality of life. a very small reduction in the likelihood of patients requiring intravenous antibiotics. 22 As As cystic fibrosis can be a severely debilitating condition in children, such data are urgently pulmonary function predicts mortality in patients with cystic fibrosis, 23 it can be expected required to enable the use of rhDNase to be justified if subjective benefit can be demthat this treatment might lead to an increased life expectancy but there have, as yet, been no onstrated even in the absence of changes in lung function. long term studies to examine this.
rhDNase is not licensed for use in children under the age of five years because of limited data on its use in this age group. Nevertheless,   The only published data available are for it is likely that some young children with suppurative lung disease will benefit, although this patients with moderately severe suppurative disease with a forced vital capacity of >40% may be difficult to quantify because of the problem of obtaining reliable pulmonary funcpredicted. One report suggests that a similar degree of benefit is obtained in patients with tion measurements. more severe disease 24 but that the time taken to achieve a plateau is longer. 
